Dirk De Ruysscher1, Patrick Vincent Granton2, Natasja Gaby Lieuwes2, Stefan van Hoof2, Lutz Wollin3, Birgit Weynand4, Anne-Marie Dingemans5, Frank Verhaegen2, Ludwig Dubois6. 1. Department of Radiation Oncology (Maastro), GROW - School for Oncology and Developmental Biology, Maastricht University Medical Center, The Netherlands; Department of Radiation Oncology, KU Leuven, Belgium. 2. Department of Radiation Oncology (Maastro), GROW - School for Oncology and Developmental Biology, Maastricht University Medical Center, The Netherlands. 3. Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany. 4. Department of Pathology, KU Leuven, Belgium. 5. Department of Pulmonology, GROW - School for Oncology and Developmental Biology, Maastricht University Medical Center, The Netherlands. 6. Department of Radiation Oncology (Maastro), GROW - School for Oncology and Developmental Biology, Maastricht University Medical Center, The Netherlands. Electronic address: ludwig.dubois@maastrichtuniversity.nl.
Abstract
BACKGROUND: Nintedanib has anti-fibrotic and anti-inflammatory activity and is approved for the treatment of idiopathic pulmonary fibrosis. The aim of this study was to noninvasively assess the efficacy of nintedanib in a mouse model of partial lung irradiation to prevent radiation-induced lung damage (RILD). METHODS: 266 C57BL/6 adult male mice were irradiated with a single radiation dose (0, 4, 8, 12, 16 or 20Gy) using parallel-opposed fields targeting the upper right lung using a precision image-guided small animal irradiator sparing heart and spine based on micro-CT images. One week post irradiation, mice were randomized across nintedanib daily oral gavage treatment (0, 30 or 60mg/kg). CT density analysis of the lungs was performed on monthly acquired micro-CT images. After 39weeks, lungs were processed to evaluate the fibrotic phenotype. RESULTS: Although the CT density increase correlated with the radiation dose, nintedanib did not influence this relationship. Immunohistochemical analysis confirmed the ability of nintedanib to reduce the microscopic fibrotic phenotype, in particular interstitial edema, interstitial and perivascular fibrosis and inflammation, and vasculitis. CONCLUSIONS: Nintedanib reduces radiation-induced lung fibrosis after partial lung irradiation without adverse effects, however, noninvasive CT imaging measuring electron density cannot be applied for monitoring its effects.
BACKGROUND:Nintedanib has anti-fibrotic and anti-inflammatory activity and is approved for the treatment of idiopathic pulmonary fibrosis. The aim of this study was to noninvasively assess the efficacy of nintedanib in a mouse model of partial lung irradiation to prevent radiation-induced lung damage (RILD). METHODS: 266 C57BL/6 adult male mice were irradiated with a single radiation dose (0, 4, 8, 12, 16 or 20Gy) using parallel-opposed fields targeting the upper right lung using a precision image-guided small animal irradiator sparing heart and spine based on micro-CT images. One week post irradiation, mice were randomized across nintedanib daily oral gavage treatment (0, 30 or 60mg/kg). CT density analysis of the lungs was performed on monthly acquired micro-CT images. After 39weeks, lungs were processed to evaluate the fibrotic phenotype. RESULTS: Although the CT density increase correlated with the radiation dose, nintedanib did not influence this relationship. Immunohistochemical analysis confirmed the ability of nintedanib to reduce the microscopic fibrotic phenotype, in particular interstitial edema, interstitial and perivascular fibrosis and inflammation, and vasculitis. CONCLUSIONS:Nintedanib reduces radiation-induced lung fibrosis after partial lung irradiation without adverse effects, however, noninvasive CT imaging measuring electron density cannot be applied for monitoring its effects.
Authors: Lucas Persoon; Stefan van Hoof; Frank van der Kruijssen; Patrick Granton; Andrea Sanchez Rivero; Harold Beunk; Ludwig Dubois; Jan-Willem Doosje; Frank Verhaegen Journal: Br J Radiol Date: 2018-10-11 Impact factor: 3.039
Authors: Carmen I Rios; David R Cassatt; Brynn A Hollingsworth; Merriline M Satyamitra; Yeabsera S Tadesse; Lanyn P Taliaferro; Thomas A Winters; Andrea L DiCarlo Journal: Radiat Res Date: 2021-01-01 Impact factor: 2.841
Authors: Mihaela Ghita; Victoria Dunne; Gerard G Hanna; Kevin M Prise; Jaqueline P Williams; Karl T Butterworth Journal: Br J Radiol Date: 2019-02-13 Impact factor: 3.039
Authors: Alexander N Hanania; Walker Mainwaring; Yohannes T Ghebre; Nicola A Hanania; Michelle Ludwig Journal: Chest Date: 2019-04-15 Impact factor: 9.410
Authors: Mihaela Ghita; Kathryn H Brown; Olivia J Kelada; Edward E Graves; Karl T Butterworth Journal: Cancers (Basel) Date: 2019-02-01 Impact factor: 6.639
Authors: Lutz Wollin; Jörg H W Distler; Elizabeth F Redente; David W H Riches; Susanne Stowasser; Rozsa Schlenker-Herceg; Toby M Maher; Martin Kolb Journal: Eur Respir J Date: 2019-09-19 Impact factor: 16.671
Authors: Linda Spiegelberg; Stefan J van Hoof; Rianne Biemans; Natasja G Lieuwes; Damiënne Marcus; Raymon Niemans; Jan Theys; Ala Yaromina; Philippe Lambin; Frank Verhaegen; Ludwig J Dubois Journal: Radiother Oncol Date: 2019-08-17 Impact factor: 6.280
Authors: Kathryn H Brown; Mihaela Ghita; Ludwig J Dubois; Dirk de Ruysscher; Kevin M Prise; Frank Verhaegen; Karl T Butterworth Journal: Clin Transl Radiat Oncol Date: 2022-04-06
Authors: Georgios Lappas; Nick Staut; Natasja G Lieuwes; Rianne Biemans; Cecile J A Wolfs; Stefan J van Hoof; Ludwig J Dubois; Frank Verhaegen Journal: Phys Imaging Radiat Oncol Date: 2022-01-24